RATIONALE: Minocycline has long been applied to various infectious diseases as a tetracycline antibiotic and recently has found new application in the treatment of brain diseases such as stroke and multiple sclerosis. In addition, minocycline has also been suggested as an effective drug for psychiatric diseases. These suggestions imply that minocycline may modulate our mental activities, while the underlying mechanism remains to be clarified. OBJECTIVE: To investigate how minocycline influences human mental activity, we experimentally examined how minocycline works on human social decision making in a double-blind randomized trial. METHODS:Forty-nine healthy volunteers were administered minocycline or placebo over four days, after which they played (1) a trust game, in which they decided how much to trust an anonymous partner, and (2) a dictator game, in which they decided how to divide resources between themselves and an anonymous partner. RESULTS: The minocycline group did not display increased trusting behavior or more altruistic resource allocation. In fact, the minocycline group displayed a slight reduction in trusting behavior. However, the minocycline group did show a strong positive correlation between the degree of risk taking in the trust game and in a separate evaluation of others' trustworthiness, whereas the placebo group showed no such correlation. CONCLUSIONS: These results suggest that minocycline led to more rational decision-making strategies, possibly by increasing emotion regulation. Since minocycline is a well-known inhibitor of microglial activation, our findings may open a new optional pathway for treating mental states in which a component of rational decision making is impaired.
RCT Entities:
RATIONALE: Minocycline has long been applied to various infectious diseases as a tetracycline antibiotic and recently has found new application in the treatment of brain diseases such as stroke and multiple sclerosis. In addition, minocycline has also been suggested as an effective drug for psychiatric diseases. These suggestions imply that minocycline may modulate our mental activities, while the underlying mechanism remains to be clarified. OBJECTIVE: To investigate how minocycline influences human mental activity, we experimentally examined how minocycline works on human social decision making in a double-blind randomized trial. METHODS: Forty-nine healthy volunteers were administered minocycline or placebo over four days, after which they played (1) a trust game, in which they decided how much to trust an anonymous partner, and (2) a dictator game, in which they decided how to divide resources between themselves and an anonymous partner. RESULTS: The minocycline group did not display increased trusting behavior or more altruistic resource allocation. In fact, the minocycline group displayed a slight reduction in trusting behavior. However, the minocycline group did show a strong positive correlation between the degree of risk taking in the trust game and in a separate evaluation of others' trustworthiness, whereas the placebo group showed no such correlation. CONCLUSIONS: These results suggest that minocycline led to more rational decision-making strategies, possibly by increasing emotion regulation. Since minocycline is a well-known inhibitor of microglial activation, our findings may open a new optional pathway for treating mental states in which a component of rational decision making is impaired.
Authors: Yue Wu; Erin L Lousberg; Lachlan M Moldenhauer; John D Hayball; Sarah A Robertson; Janet K Coller; Linda R Watkins; Andrew A Somogyi; Mark R Hutchinson Journal: Brain Behav Immun Date: 2011-01-27 Impact factor: 7.217
Authors: Johann Steiner; Hendrik Bielau; Ralf Brisch; Peter Danos; Oliver Ullrich; Christian Mawrin; Hans-Gert Bernstein; Bernhard Bogerts Journal: J Psychiatr Res Date: 2006-12-15 Impact factor: 4.791
Authors: Matthew G Frank; Michael V Baratta; David B Sprunger; Linda R Watkins; Steven F Maier Journal: Brain Behav Immun Date: 2006-05-02 Impact factor: 7.217
Authors: Janine Doorduin; Erik F J de Vries; Antoon T M Willemsen; Jan Cees de Groot; Rudi A Dierckx; Hans C Klein Journal: J Nucl Med Date: 2009-10-16 Impact factor: 10.057
Authors: Caroline A Arout; Andrew J Waters; R Ross MacLean; Peggy Compton; Mehmet Sofuoglu Journal: Psychopharmacology (Berl) Date: 2018-12-18 Impact factor: 4.530
Authors: Ismene L Petrakis; Elizabeth Ralevski; Ralitza Gueorguieva; Matthew E Sloan; Lesley Devine; Gihyun Yoon; Albert J Arias; Mehmet Sofuoglu Journal: Psychopharmacology (Berl) Date: 2019-03-27 Impact factor: 4.530
Authors: Iris E Sommer; Roos van Westrhenen; Marieke J H Begemann; Lot D de Witte; Stefan Leucht; René S Kahn Journal: Schizophr Bull Date: 2013-10-08 Impact factor: 9.306
Authors: Iris E Sommer; Shiral S Gangadin; Lot D de Witte; Sanne Koops; C van Baal; Sabine Bahn; Hemmo Drexhage; N E M van Haren; Wim Veling; R Bruggeman; Peter Martens; Sybren Wiersma; Selene R T Veerman; Koen P Grootens; Nico van Beveren; Rene S Kahn; Marieke J H Begemann Journal: Schizophr Bull Date: 2021-07-08 Impact factor: 9.306